scholarly journals Primary Patency Rates of Endovascular Interventions in Hemodialysis Patients with Central Venous Stenosis and Occlusions

2021 ◽  
Vol 1 (1) ◽  
pp. 17-21
Author(s):  
Mehmet Burak Çildağ ◽  
Veli Süha Öztürk ◽  
Recep Özgür ◽  
Ömer Faruk Kutsi Köseoğlu
Keyword(s):  
Hemodialysis Patients ◽  
Primary Patency ◽  
Central Venous ◽  
Central Venous Stenosis ◽  
Endovascular Interventions ◽  
Venous Stenosis

Stent-Graft Length Is Associated with Decreased Patency in Treatment of Central Venous Stenosis in Hemodialysis Patients

2019 ◽  
Vol 59 ◽  
pp. 225-230 ◽  
Author(s):  
Mina L. Boutrous ◽  
Alejandro C. Alvarez ◽  
Obi T. Okoye ◽  
Jennifer C. Laws ◽  
Donald L. Jacobs ◽  
...  
Keyword(s):  
Stent Graft ◽  
Hemodialysis Patients ◽  
Central Venous ◽  
Central Venous Stenosis ◽  
Venous Stenosis ◽  
Graft Length

scholarly journals Comparison of Management for Central Venous Stenosis With or Without Previous Catheter Placement

2021 ◽  
Vol 12 ◽  
Author(s):  
Wei Ma ◽  
Zhengde Zhao ◽  
Qining Fu ◽  
Liangzhu Hu ◽  
Xia Zhao ◽  
...  
Keyword(s):  
Patency Rate ◽  
Bare Metal Stent ◽  
Primary Patency ◽  
Catheter Placement ◽  
Bare Metal ◽  
Metal Stent ◽  
Central Venous ◽  
Primary Patency Rate ◽  
Central Venous Stenosis ◽  
Venous Stenosis

Objective: To compare central venous stenosis/occlusion with or without previous jugular catheter placement history.Methods: Data of patients with central vein stenosis/occlusion receiving endovascular intervention in our hospital from January 2015 to December 2018 were collected and analyzed.Results: Twenty-nine patients with previous jugular catheter placement history (CVC group) and 33 patients (excluded two with technical failure) without such history (non-CVC group) are included in this study. Previous jugular catheter placement history raised the risk of postintervention recurrence 1.02 times (CVC group vs. non-CVC group, HR = 2.02 95%CI: 0.91–4.48). The primary patency rate at 6, 12, 18, and 24 months was 76.9, 54.2, 45.5, and 25.0% separately in the CVC group and 80.6, 70.0, 67.9, and 44.4% separately in the non-CVC group. The assisted primary patency rate at 6, 12, 18, and 24 months was 92.3, 91.7, 86.4, and 68.8% separately in the CVC group and 93.5, 90.0, 82.1, and 61.1% separately in the non-CVC group. Patients in the CVC group received a higher frequency of reintervention (0.7 times/year/patient vs. 0.3 times/year/patient). There was no significant difference in the assisted primary patency rate between the two groups. Different primary interventions (angioplasty alone, bare metal stent, stent graft) did not affect primary patency and assisted primary patency, but percutaneous transluminal stenting (PTS) with a bare metal stent had a significant lower primary patency rate between 3 and 24 months compared with PTS with a stent graft (p = 0.011).Conclusion: Central venous stenosis/occlusion with a previous jugular catheter placement history develops symptoms earlier and had a worse prognosis after endovascular intervention. More efforts are needed to carry out end-stage kidney disease life plan to reduce the harm of evitable catheter placement.

Medial claviculectomy for the treatment of recalcitrant central venous stenosis of hemodialysis patients

2019 ◽  
Vol 7 (3) ◽  
pp. 420-427
Author(s):  
Philip L. Auyang ◽  
Yusuf Chauhan ◽  
Thomas M. Loh ◽  
Matthew E. Bennett ◽  
Eric K. Peden
Keyword(s):  
Hemodialysis Patients ◽  
Central Venous ◽  
Central Venous Stenosis ◽  
Venous Stenosis

Primary and secondary patencies of transposed femoral vein fistulas are significantly greater than with the HeRO graft

2017 ◽  
Vol 18 (3) ◽  
pp. 232-237 ◽  
Author(s):  
Eric D. Ladenheim ◽  
Dzenan Lulic ◽  
Craig Lum ◽  
Sid Agrawal
Keyword(s):  
Wound Healing ◽  
Femoral Vein ◽  
Primary Patency ◽  
Secondary Patency ◽  
Central Venous ◽  
Av Fistula ◽  
Central Venous Stenosis ◽  
Venous Stenosis ◽  
One Year ◽  
The One

Introduction For access-challenged patients with bilateral upper extremity central venous stenosis, solutions include the Hemodialysis Reliable Outflow (HeRO) device or an autogenous AV fistula in the lower limb. We evaluated HeRO grafts and transpositions of the femoral vein in maintaining primary and secondary patency. Methods We retrospectively analyzed 40 patients with a HeRO device and 18 patients with superficial femoral artery to transposed femoral vein autogenous arteriovenous fistula (SFA-tFV). All patients had bilateral central venous obstruction. All procedures were outpatient performed by a single surgeon at one center between 2009-2015. Operative details, intraoperative flows, and flows at the first-week postoperative visit were analyzed, as were primary and secondary patency and intervention rates. Complications were compared between groups. Results The one-year cumulative primary patency was 30% for HeRO grafts and 79% for SFA-tFV fistulas (p = 0.0001); secondary patency was 71% for HeRO grafts and 93% for SFA-tFV fistulas (p = 0.03). To maintain patency, HeRO patients required a mean 2.1 interventions per year and thigh fistula patients required a mean 0.4 interventions per year. Thirty-seven percent of thigh fistula patients had a hematoma or seroma versus 5% of HeRO patients and 17% of thigh fistula patients experienced delayed wound healing versus 2.5% of HeRO patients (p<0.05). None of the thigh fistula patients had distal ischemia. Conclusions HeRO patients had lower primary and secondary patency rates versus thigh fistula patients and HeRO grafts required five-fold more interventions to maintain secondary patency. However, patients with thigh fistulas had significantly more wound healing problems. Thus, the SFA-tFV has become our access of choice for patients with bilateral central venous stenosis.

Sign in / Sign up

Export Citation Format

Share Document